HRP20200229T1 - Uporaba izvanstaničnih nukleosoma kao biomarkera u fekalnim uzorcima - Google Patents
Uporaba izvanstaničnih nukleosoma kao biomarkera u fekalnim uzorcima Download PDFInfo
- Publication number
- HRP20200229T1 HRP20200229T1 HRP20200229TT HRP20200229T HRP20200229T1 HR P20200229 T1 HRP20200229 T1 HR P20200229T1 HR P20200229T T HRP20200229T T HR P20200229TT HR P20200229 T HRP20200229 T HR P20200229T HR P20200229 T1 HRP20200229 T1 HR P20200229T1
- Authority
- HR
- Croatia
- Prior art keywords
- extracellular
- nucleosomes
- epigenetic
- fecal sample
- epigenetic property
- Prior art date
Links
- 108010047956 Nucleosomes Proteins 0.000 title claims 31
- 210000001623 nucleosome Anatomy 0.000 title claims 31
- 230000002550 fecal effect Effects 0.000 title claims 18
- 239000000090 biomarker Substances 0.000 title claims 3
- 230000001973 epigenetic effect Effects 0.000 claims 20
- 238000000034 method Methods 0.000 claims 11
- 108010033040 Histones Proteins 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 201000002758 colorectal adenoma Diseases 0.000 claims 6
- 208000022131 polyp of large intestine Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 230000008836 DNA modification Effects 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 102100023919 Histone H2A.Z Human genes 0.000 claims 2
- 101000905054 Homo sapiens Histone H2A.Z Proteins 0.000 claims 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Nonanedioid acid Natural products OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 230000001323 posttranslational effect Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000037062 Polyps Diseases 0.000 claims 1
- 238000002487 chromatin immunoprecipitation Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (14)
1. Uporaba izvanstaničnih nukleosoma kao biomarkera u fekalnim uzorcima za dijagnozu ili detekciju kolorektalnog karcinoma, kolorektalnog adenoma ili polipa.
2. Uporaba prema zahtjevu 1, pri čemu biomarker je epigenetsko svojstvo izvanstaničnog nukleosoma.
3. Uporaba prema zahtjevu 1 ili zahtjevu 2, pri čemu je izvanstanični nukleosom mononukleosom ili oligonukleosom.
4. Postupak za dijagnosticiranje ili detektiranje kolorektalnog karcinoma, kolorektalnog adenoma ili polipa kod životinjskog ili ljudskog subjekta koji sadrži korake:
(i) detektiranje ili mjerenje epigenetskog svojstva izvanstaničnih nukleosoma u fekalnom uzorku dobivenom od subjekta; i
(ii) korištenje izmjerene razine izvanstaničnih nukleosoma koji sadrži spomenuto epigenetsko svojstvo kao indikaciju prisutnosti spomenute bolesti u subjektu.
5. Uporaba ili postupak prema bilo kojem od zahtjeva 2 do 4, pri čemu je epigenetsko svojstvo odabrano od: posttranslacijske modifikacije histona, varijante histona ili izoforma, DNA modifikacije ili proteina aduciranog na nukleosom, poput DNA modifikacije odabrane od 5-metilcitozina, jedne ili više varijanti histona odabranih od gama-H2AX i H2AZ i jedne ili više modifikacija histona odabranih od: H3K9Me3, H3K9Ac, H3K27Me3, H4K16Ac, H4K20Me3, ubikvitil-H2A i H4PanAc (pan-acetiliraniH4).
6. Postupak praćenja efikasnosti terapije kod životinjskog ili ljudskog subjekta koji ima, sumnja se da ima, ili ima predispozicije za kolorektalni karcinom, kolorektalni adenom ili polip koji sadrži korake:
(i) mjerenje epigenetskog svojstva izvanstaničnih nukleosoma u fekalnom uzorku dobivenom od subjekta; i
(ii) korištenje razine izvanstaničnih nukleosoma koji sadrže spomenuto epigenetsko svojstvo uspoređeno s ranijim uzorkom uzetim od spomenutog subjekta kao indikaciju efikasnosti spomenute terapije.
7. Postupak za određivanje prognoze životinjskog ili ljudskog subjekta s kolorektalnim karcinomom, kolorektalnim adenomom ili polipom koji sadrži korake:
(i) mjerenje epigenetskog svojstva izvanstaničnih nukleosoma u fekalnom uzorku dobivenom od subjekta; i
(ii) korištenje izmjerene razine izvanstaničnih nukleosoma koji sadrže spomenuto epigenetsko svojstvo kao indikaciju za prognozu kolorektalnog karcinoma, kolorektalnog adenoma ili polipa.
8. Postupak za određivanje porijekla stanice fekalnog izvanstaničnog nukleosoma kod životinjskog ili ljudskog subjekta koji sadrži korake:
(i) detektiranje ili mjerenje epigenetskog svojstva izvanstaničnih nukleosoma u fekalnom uzorku dobivenom od subjekta; i
(ii) korištenje izmjerene razine izvanstaničnih nukleosoma koji sadrži spomenuto epigenetsko svojstvo kao indikaciju dolaze li izvanstanični nukleosomi iz zdravih gastroenteroloških stanica, stanica kolorektalnog karcinoma, stanica polipa, stanica s drugim lezijama ili bilo koje njihove mješavine.
9. Uporaba ili postupak prema bilo kojem od zahtjeva 1 do 8, pri čemu spomenuto detektiranje ili mjerenje sadrži imunoanalizu, imunokemijsku, masenu spektroskopiju, kromatografsku, kromatinsku imunoprecipitaciju ili biosenzorsku metodu.
10. Uporaba ili postupak prema bilo kojem od zahtjeva 1 do 9, pri čemu dva ili više mjerenja izvanstaničnih nukleosoma per se i/ili epigenetskih svojstava izvanstaničnih nukleosoma su provedena kao panel svojstava nukleosoma.
11. Uporaba seta koji sadrži jedan ili više vezujućih agensa sposobnih za detektiranje i/ili kvantificiranje epigenetskog svojstva fekalnog izvanstaničnog nukleosoma za dijagnozu ili detekciju kolorektalnog karcinoma, kolorektalnog adenoma ili polipa u fekalnom uzorku.
12. Postupak za detektiranje ili kvantificiranje epigenetskog svojstva izvanstaničnog nukleosoma u fekalnom uzorku dobivenom od životinjskog ili ljudskog subjekta koji sadrži korake:
(i) kontaktiranje fekalnog uzorka s prvim vezujućim agensom koji se veže na izvanstanične nukleosome ili njihov dio;
(ii) kontaktiranje fekalnog uzorka ili izvanstaničnih nukleosoma s drugim vezujućim agensom koji se veže na epigenetsko svojstvo unutar spomenutih izvanstaničnih nukleosoma;
(iii) detektiranje ili kvantifikacija vezanja spomenutog drugog vezujućeg agensa na epigenetsko svojstvo unutar spomenutih izvanstaničnih nukleosoma u fekalnom uzorku; i
(iv) korištenje prisutnosti, stupnja ili količine takvog vezanja kao mjeru prisutnosti izvanstaničnih nukleosoma koji sadrže spomenuto epigenetsko svojstvo u fekalnom uzorku.
13. Postupak za detektiranje ili kvantificiranje epigenetskog svojstva izvanstaničnog nukleosoma u fekalnom uzorku dobivenom od životinjskog ili ljudskog subjekta koji sadrži korake:
(i) kontaktiranje fekalnog uzorka s prvim vezujućim agensom koji se veže na epigenetsku značajku unutar navedenih nukleozoma bez stanica;
(ii) kontaktiranje fekalnog uzorka ili nukleosoma bez stanica s drugim sredstvom za vezanje koje se veže na nukleosome bez stanica ili na njihovu komponentu;
(iii) otkrivanje ili kvantificiranje vezanja navedenog drugog vezivnog agensa na nukleozome bez stanica ili njegove komponente u fekalnom uzorku; i
(iv) primjenom prisutnosti, stupnja ili količine takvog vezanja kao mjere prisutnosti nukleozoma bez stanica koji sadrže spomenuto epigenetsko obilježje u uzorku fekalija.
14. Postupak prema zahtjevu 12 ili zahtjevu 13, pri čemu je epigenetsko svojstvo odabrano od: posttranslacijske modifikacije histona, varijante histona ili izoforma, DNA modifikacije ili proteina aduciranog na spomenuti nukleosom, poput DNA modifikacije odabrane od 5-metilcitozina, jedne ili više varijanti histona odabranih od gama-H2AX i H2AZ i jedne ili više modifikacija histona odabranih od: H3K9Me3, H3K9Ac, H3K27Me3, H4K16Ac, H4K20Me3, ubikvitil-H2A i H4PanAc (pan-acetiliraniH4).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1511542.1A GB201511542D0 (en) | 2015-07-01 | 2015-07-01 | Use of cell free nucleosomes as biomarkers |
PCT/GB2016/051995 WO2017001864A1 (en) | 2015-07-01 | 2016-07-01 | Use of cell-free nucleosomes as biomarkers in fecal samples |
EP16736595.6A EP3317672B1 (en) | 2015-07-01 | 2016-07-01 | Use of cell-free nucleosomes as biomarkers in fecal samples |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200229T1 true HRP20200229T1 (hr) | 2020-11-13 |
Family
ID=53872511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200229TT HRP20200229T1 (hr) | 2015-07-01 | 2020-02-11 | Uporaba izvanstaničnih nukleosoma kao biomarkera u fekalnim uzorcima |
Country Status (8)
Country | Link |
---|---|
US (1) | US20180305759A1 (hr) |
EP (1) | EP3317672B1 (hr) |
DK (1) | DK3317672T3 (hr) |
ES (1) | ES2775178T3 (hr) |
GB (1) | GB201511542D0 (hr) |
HR (1) | HRP20200229T1 (hr) |
PL (1) | PL3317672T3 (hr) |
WO (1) | WO2017001864A1 (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020210754A1 (en) | 2019-04-10 | 2020-10-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computational filtering of methylated sequence data for predictive modeling |
US20230003735A1 (en) * | 2019-12-02 | 2023-01-05 | Belgian Volition Srl | Use of cell free nucleosomes as biomarkers |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201115095D0 (en) * | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
AU2012349855B2 (en) * | 2011-12-07 | 2017-12-07 | Belgian Volition Sprl | Method for detecting nucleosome adducts |
GB201303575D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for detecting histone modifications in nucleosomes |
-
2015
- 2015-07-01 GB GBGB1511542.1A patent/GB201511542D0/en not_active Ceased
-
2016
- 2016-07-01 ES ES16736595T patent/ES2775178T3/es active Active
- 2016-07-01 DK DK16736595.6T patent/DK3317672T3/da active
- 2016-07-01 EP EP16736595.6A patent/EP3317672B1/en active Active
- 2016-07-01 PL PL16736595T patent/PL3317672T3/pl unknown
- 2016-07-01 US US15/738,084 patent/US20180305759A1/en not_active Abandoned
- 2016-07-01 WO PCT/GB2016/051995 patent/WO2017001864A1/en active Application Filing
-
2020
- 2020-02-11 HR HRP20200229TT patent/HRP20200229T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP3317672B1 (en) | 2019-12-11 |
WO2017001864A1 (en) | 2017-01-05 |
US20180305759A1 (en) | 2018-10-25 |
GB201511542D0 (en) | 2015-08-12 |
DK3317672T3 (da) | 2020-03-16 |
ES2775178T3 (es) | 2020-07-24 |
EP3317672A1 (en) | 2018-05-09 |
PL3317672T3 (pl) | 2020-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2634266C2 (ru) | Способ детекции аддуктов нуклеосом | |
Tanak et al. | Multiplexed cytokine detection using electrochemical point-of-care sensing device towards rapid sepsis endotyping | |
RU2014112350A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
RU2014112348A (ru) | Способ детекции нуклеосом, содержащих гистоновые варианты | |
Saito et al. | High expression of glypican-1 predicts dissemination and poor prognosis in glioblastomas | |
HRP20130127T1 (hr) | Prediktivni biomarkeri bubrežne sigurnosti i potpisi biomarkera za praä†enje funkcije bubrega | |
JP2014529405A5 (hr) | ||
BR112012019542A2 (pt) | "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit" | |
WO2007127749A3 (en) | Predicting mortality and detecting severe disease | |
BRPI0809938B8 (pt) | sistemas de medição de propriedade de amostra, métodos de determinação do nível de constituinte em fluido e de minimização do impacto de erros potenciais | |
JP2014531573A5 (hr) | ||
WO2006026020A3 (en) | Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin | |
JP2018529931A5 (hr) | ||
George et al. | Profiling of kidney injury biomarkers in patients receiving cisplatin: time‐dependent changes in the absence of clinical nephrotoxicity | |
DK1725881T3 (da) | Testorgan-analysesystem med kontaktflader, som er dækket af hårdt materiale | |
HRP20200229T1 (hr) | Uporaba izvanstaničnih nukleosoma kao biomarkera u fekalnim uzorcima | |
JP2008514209A5 (hr) | ||
CA2623653A1 (en) | Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis | |
Savukoski et al. | Elevation of cardiac troponins measured after recreational resistance training | |
RU2019104870A (ru) | Комбинированный тест на наличие колоректального рака | |
ES2772701T3 (es) | Uso de nucleosomas libres de células como biomarcadores en muestras de esputo | |
JP2019510974A5 (hr) | ||
Bronzwaer et al. | Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening | |
RU2009112392A (ru) | Импедансные системы, устройства и способы для оценки ионтофоретических свойств соединений | |
ATE549417T1 (de) | Diagnoseverfahren für osteoarthritis |